SCLP vs. PRTC, HZD, AVCT, VRP, FARN, ARIX, CIR, BVXP, 4BB, and TILS
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.
Scancell vs. Its Competitors
Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Scancell has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.
Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Scancell's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.
PureTech Health has a consensus price target of GBX 455, indicating a potential upside of 240.06%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Scancell.
0.9% of Scancell shares are held by institutional investors. Comparatively, 53.1% of PureTech Health shares are held by institutional investors. 15.5% of Scancell shares are held by company insiders. Comparatively, 13.4% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
PureTech Health beats Scancell on 10 of the 14 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
This page (LON:SCLP) was last updated on 10/9/2025 by MarketBeat.com Staff
